Therapeutic potential of naturally modified mucoadhesive fluconazole tablets against vaginal infection

Vaginitis is a very common gynaecological problem in women of all age groups. Fluconazole chemically known as 2-(2, 4-diflurophenyl)-1, 3-bis (1H-1, 2, 4-triazole-1-yl)-2-propanol. Is a synthetic triazole derivative antifungal agent that is effective against a wide range of systemic and superficial fungal Infections. The mucoadhesive vaginal tablets were prepared by the direct compression method. FTIR had employed to study drug excipient incompatibility. The mucoadhesive vaginal tablet was evaluated for % swelling index, Muco-adhesive strength, drug content, % drug release, and Invitro Dissolution release. It was observed that more than 85% drug was released within 480 min in direct compression method formulations (FLZ1-FLZ9). Formulation FLZ3 that containing 6% of eudragit revealed maximum drug release profile up to 89.20±0.343% within 480 min, whereas formulation FLZ5 showed 87.20±0.765% drug release. The best formulation was compared with the marketed formulations for in-vitro drug release and showed almost similar drug release. Stability study shows no changes. This study may prove potential vaginal formulation of Fluconazole against bacterial vaginosis.